'Raking in billions': Report shows drug middlemen jack up prices by nearly 8,000%
The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug middlemen are marking up the prices of specialty generic drugs dispensed at their affiliated pharmacies by hundreds—and in some cases,
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
FTC releases second report slamming pharmacy benefit managers
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.
FTC releases new findings in drug price inflation investigation
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of prescription drugs.
Report Reveals Billions Made from Generic Drug Price Hikes
A recent Federal Trade Commission report highlights a concerning trend in the pharmaceutical industry, where pharmacy benefit managers (PBMs) are accused of significantly inflating the cost of prescription drugs.
FTC says Minnesota-based Optum, et al., inflate cancer drug prices 1,000%
Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than 1,000-percent.
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
Michigan Advance2d
Regulator accuses drug middlemen of wild price hikes, possibly steering business to themselves
The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...
Morningstar5d
FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%
CVS responds by saying regulator's latest report is 'inappropriate and misleading' The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday ...
Insurancenewsnet.com2d
Arkansas lawmakers seek to ban prescription drug middlemen from owning pharmacies in the state
A proposed Arkansas law would forbid pharmacy benefit managers (PBMs) from holding or acquiring interest in retail pharmacy ...
MedCity News4d
Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings
On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark ...
Morningstar3d
UnitedHealth fights back: Blame drugmakers for high costs, not the 'middlemen.'
See: FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%. Also read: UnitedHealthcare head Brian Thompson's killing shines light on health-insurance denial rates.
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...
Columbus joins national fight accusing drug manufacturers of inflating insulin prices
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...